Article

September 1, 2003

Study links OAG, thyroid disease

Fort Lauderdale, FL-Analyses of data collected in the Blue Mountains Eye Study (BMES) provide evidence for a relationship between open-angle glaucoma (OAG) and thyroid disease, and particularly hypothyroidism, said Anne J. Lee, MBBS, at the annual meeting of the Association for Research in Vision and Ophthalmology.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos

(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy

$(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD$

(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?

(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging

(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD

(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD

(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD

(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD

(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT

Related Content

Nicox completes phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertension

June 30th 2025

Nicox completes phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertension

3 Things You Should Know About the GA Pipeline

June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Nanoscope Therapeutics forms Vision Advisory Committee

June 30th 2025

Nanoscope Therapeutics forms Vision Advisory Committee

Patient-Centered Treatment Strategies in the Management of nAMD and DME

May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Q&A: Sevgi Gurkan, MD, on the PER-001 for glaucoma and DME

June 28th 2025

Q&A: Sevgi Gurkan, MD, on the PER-001 for glaucoma and DME

PYC to finalize registrational study for RP11 after positive FDA feedback

June 28th 2025

PYC to finalize registrational study for RP11 after positive FDA feedback

Related Content

Nicox completes phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertension

June 30th 2025

Nicox completes phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertension

3 Things You Should Know About the GA Pipeline

June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Nanoscope Therapeutics forms Vision Advisory Committee

June 30th 2025

Nanoscope Therapeutics forms Vision Advisory Committee

Patient-Centered Treatment Strategies in the Management of nAMD and DME

May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Q&A: Sevgi Gurkan, MD, on the PER-001 for glaucoma and DME

June 28th 2025

Q&A: Sevgi Gurkan, MD, on the PER-001 for glaucoma and DME

PYC to finalize registrational study for RP11 after positive FDA feedback

June 28th 2025

PYC to finalize registrational study for RP11 after positive FDA feedback

Editorial Board

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.